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Alpha-radioimmunotherapy as a novel 
therapeutic option against metastasis of 
gastric cancer 
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 Introduction 
1.1  Gastric cancer 
Gastric cancer (GC) is one of the main causes of cancer-related death 
worldwide.(1) About 952,000 new cases diagnosed in 2012. GG is more 
common in Asia than other area; the Republic of Korea comes to the 
highest rate, followed by Mongolia and Japan. It is more common in older 
adults than the young, and men tend to be twice higher than women. The 
bacterium Helicobacter pylori, tobacco use and consumption of alcoholic 
drinks and processed meat are raised as the cause of GC. GC is curable at 
early stage, however, because of the asymptomatic most patients are 
diagnosed at late stage and they already have metastasis at the time of 
diagnosis. Currently, the standard therapeutic options for GC are surgery, 
radiotherapy, chemotherapy, targeted therapy and Immunotherapy. 
 
1.1.1 Peritoneal metastasis of gastric cancer 
Metastatic dissemination of GC to the peritoneal cavity frequently occurs 
during the progression of this disease and is the main form of GC relapse 
after surgical resection. The prognosis for peritoneal metastasis of gastric 
cancer (PMGC) or its associated clinical condition (peritoneal 
carcinomatosis) is extremely poor and, because no effective therapeutics 
have been established, the mean survival time is only 4 months.(2) 
 
1.1.2 HER2 expression in GC 
Recent advances in the molecular dissection of GC have helped to identify 
reliable predictive biomarkers, allowing introduction of molecular targeted 
drug therapy. Approximately 20% of GCs are HER2-positive.(3,4) 
Therefore, HER2 is an attractive target for GC. Trastuzumab, an 
anti-HER2 mAb, has been used previously as a targeted therapy for 
HER2-positive GC and yields excellent treatment outcomes.(4) However, 
its therapeutic efficacy is still limited for patients with PMGC. Novel 
antitumor strategies are thus still required to improve the clinical outcomes 
for GC patients, particularly those with PMGC. 
 
1.2 Radioimmunotherapy 
Radioimmunotherapy is a targeted radioisotope treatment method that uses 
an antibody as a carrier of therapeutic radioisotopes and has considerable 
advantages when used against micrometastatic or disseminated tumors.(5–
8) The selective targeting of radioisotopes to the tumor using a radiolabeled 
cancer-specific antibody enables the delivery of a high dose of radiation 
directly to cancer cells while minimizing the exposure of normal cells.  
 
1.2.1 Alpha-particle 
Among the radioisotopes used for RIT, alpha-particle emitting radioisotope 
(α-RI) is of particular interest because it emits highly cytotoxic α-particles. 
Alpha-particles emitted through the decay deposit a huge amount of energy 
(approximately 100 keV/lm) within a few cell diameters (a 55–80-lm path 
length in soft tissue) to induce irreparable DNA damage but sparing the 
surrounding normal tissue.(9,10) A single a-particle atom can kill a target 
cell, making it one of the most potent cell-killing agents available.(11,12) 
Alpha-RI is therefore particularly suited to the targeted killing of 
disseminated or micrometastatic solid tumors that are usually resistant to 
the low energy radiation used routinely in clinical settings, such as X-rays 
and b-particles. 
 
1.2.2 Astatine-211 (211At) 
 Astatine-211 (211At) is one of the attractive α-RI, which is produced via 
209Bi(α, 2n)211At reaction using cyclotron. 211At is a radiohalogen and does 
not have any stable isotopes. The half-life is 7.2 h, which tends to be short 
among therapeutic radioisotopes. 211At has two decay branches and both 
associated with α-emission. Since K X-rays is emitted by electron capture 
decay to 211Po, it enable us to get SPECT imaging to track and quantify 
211At activity and distribution. The mean linear energy transfer of 211At is 
97 keV/µm and the average energy is 6.79 MeV. The tissue range of 211At 
is 55-70 µm, which is about few cell length. 
 
  
Fig.1 Scheme of decay branches of 211At 
 
 
 
 
 
 
  
Aims 
The aim of this study is to investigate the therapeutic efficacy of α-RIT 
using 211At-trastuzumab in preclinical mouse models of HER2-positive 
PMGC. 
  
Materials and Methods 
3.1 Cells  
The human GC cell line NCI-N87 (N87) and two human breast cancer cell 
lines (SKBR3 and AU565) were purchased from ATCC (Manassas, VA, 
USA). The human GC cell line MKN45 was purchased from the Japanese 
Collection of Research Bioresources Cell Bank (Ibaraki, Japan). The 
human GC cell line MKN7 was purchased from RIKEN Cell Bank 
(Tsukuba, Japan). N87/Luc cells were established by the introduction of 
RediFect Red-FLuc-Puromycin lentiviral particles in accordance with the 
manufacturer’s instructions (PerkinElmer, Waltham, MA, USA).  
 
3.2 Antibody and reagents 
Trastuzumab, an anti-HER2 mAb, was purchased from Chugai 
Pharmaceutical (Tokyo, Japan). 
N-Succinimidyl-3-(trimethylstannyl)benzoate was purchased from Santa 
Cruz Biotechnology (Dallas, TX,USA). N-Chlorosuccinimide (NCS) was 
purchased from Tokyo Chemical Industry (Tokyo, Japan). 
 
3.3 Production of 211At   
211At was produced via the 209Bi(α, 2n)211At reaction using vertical beam 
irradiation system of AVF-960 cyclotron (Sumitomo Heavy Industries, 
Tokyo, Japan) at National Institute of Radiological Sciences (Chiba, Japan). 
(13) After irradiation, 211At was collected in chloroform with dry 
distillation and the chloroform was evaporated by heating at 90˚C under 
high-purity nitrogen (N2) gas. 
 
3.4 Immunoconjugation and astatine-211 labeling 
The 211At labeling of trastuzumab was carried out in accordance with a 
previously described direct astatination procedure.(14) Briefly, 2 µl of 
m-MeATE stock chloroform solution was taken and let the chloroform to 
be evaporated using N2 gas. m-MeATE was redissolved with 10µl of 
dimethyl sulfoxide. Trastuzumab was dissolved with 0.2 M sodium 
carbonate buffrt (pH 8.5) at a concentration of 3-5 mg/ml. m-MeATE was 
added to 1 mg of trastuzumab at the ratio 2 µl/mg and let the reaction 
continue for 30 min during gentle agitation. The immunoconjugate was 
then isolated using size exclusion chromatography with Sephadex 50 spin 
column (GE Healthcare) in PBS (730 g, 2 min, room temperature) and kept 
4˚C. Before the radiolabeling, trastuzumab solution was diluted to the 
concentration 2 mg/ml and adjusted to pH 5.5 by adding 3% of citric acid. 
NCS (10 µl, 0.04 mg/ml in methanol with 1% acetic acid) were added to 
about 37-74 MBq of dry Na211At to prepare 211At for labeling and reacted 
with 100 µl of m-MeATE-trastuzumab immnoconjugates (2 mg/ml) for 1 
min with voltexing. 3 µl of NCS (2 mg/ml) were added and mixed for 1 
min. At the end of the reaction, 5 µl of sodium ascorbate (50 mg/ml) were 
added to stop the reaction. 211At-trastuzumab was isolated using Sephadex 
50 spin column with PBS and verified by high performance liquid 
chromatography. The activities of 211At-trastuzumab pre/post-isolation 
were measured using a dose calibrator (Capintec, Ramsey, NJ, USA) and 
the labeling yield was calculated by dividing the post-isolation activity by 
the pre-isolation activity.  
 
3.5 Radiochemical Purity 
The radiochemical purity (RCP) of 211At-trastuzumab was determined by 
methanol precipitation. 211At-trastuzumab (100-200 kBq) were taken from 
the sample and added to 200 µl of 1% bovine serum albumin in PBS 
(1%BSA/PBS) in 1.5 ml tube. 500 µl of cold methanol were added and 
kept in ice for 5 min to let the protein precipitated. The tube was 
centrifuged (3000 rpm, 3 min, 4˚C) and the supernatant was removed, the 
protein bound 211At was remained in the pellet. The radioactivity of the 
tube before the pelleting and the pellet was measured using γ-counter 
(Aloka, Tokyo, Japan) with energy window 65-95 keV. The radioactivity 
of the pellet was measured. The radiochemical purity was calculated by 
dividing the radioactivity of the pellet by the applied radioactivity. 
 
3.6 Serum Stability 
The serum stability was evaluated in duplicate by measuring the RPC of 
211At-trastuzumab after 1, 3, 15, 24 h incubation with murine serum. 
211At-trastuzumab (10-12 MBq) was added to fresh prepared murine serum 
and incubated at 37˚C. At each time point, methanol precipitation was 
performed in triplicate.  
 
3.7 Western blot assay 
Western blot assay carried out as described previously.(8) Briefly, cell 
lysates was prepared in loading buffer (Cell Signaling TECHNOLOGY, 
Tokyo, Japan). Ten µg of cell lysates were loaded into SDS-PAGE gel 
(BioRad, Hercules, Tokyo) and run using an electrophoresis system. The 
proteins were transferred onto immunoblot membranes and incubated with 
primary antibodies, HER2/ErbB2 Rabbit Antibody#2242 (Cell Signaling 
TECHNOLOGY) or anti-α-Tublin Mouse mAb (DM1A) (MERCK 
MILLIPORE, Tokyo, Japan), for 1 h at room temperature followed with 
incubation with second antibodies, anti-Rabbit IgG HRP-linked Antibody 
#7074 and anti-Mouse IgG HRP-linked Antibody #7076 (Cell signaling 
TECHNOLOGY), as same condition. The band intensities were detected 
by chemiluminescence and quantified using Gene Gnome System 
(GGNOME-5) and Gene Sys software (SYNGENE, Cambridge, UK). 
 
3.8 Cell binding and Inhibition assay 
211At-trastuzumab (approximately 25,000 cpm) was incubated with 
increasing concentration of either N87 or MKN45 cell suspension (1-50 x 
105 cells/ml in 1%BSA/PBS) in 2 ml tube on ice for 1 h. For inhibition 
assay, 100-fold trastuzumab was added to the cells 5 min before incubating 
with 211At-trastuzumab. During the incubation, the mixture in the tube was 
stirred with voltex every 15 min. After 1 h incubation, the tube was 
centrifuged (1,200 rpm, 5 min, 4˚C) and the unbound 211At-trastuzumab in 
the supernatant was removed. The cells were washed twice with PBS and 
collected in polypropylene tube. The cell bound radioactivity was measured 
using a γ counter and the cell bound ratio was calculated by dividing the 
cell bound radioactivity by applied radioactivity. 
 
3.9 In vitro cytotoxicity.  
MKN45, N87, SKBR3, MKN7, and AU565 cells (2–20x103/well) were 
seeded into 96-well plates the day before the experiment. After the medium 
was removed, culture medium (100 µl) containing either PBS, trastuzumab, 
non-carrier 211At, or 211At-trastuzumab was applied to the cells, followed by 
incubation at 37°C for 24 h. The protein doses of trastuzumab and 
211At-trastuzumab were adjusted to the same amount (0.0034–0.0244 µg) 
by the addition of intact antibody. After the incubation, the medium was 
removed and the cells were washed once with PBS. Fresh medium (100 µl) 
was then added to each well and the cells were further incubated in a 
humidified atmosphere containing 5% CO2 at 37°C for 7 days. Cells were 
fixed with 4% formalin and stained with 0.05% crystal violet. The cell 
cytotoxicity was quantified by determining the color density of each well 
using Image Quant LAS4000 and Image Quant TL (GE Healthcare). 
 
3.10 Animal experiments.  
All animal experiments were approved by the Animal Care and Use 
Committee of the National Institute of Radiological Sciences at the 
National Institutes for Quantum and Radiological Science and Technology 
(Chiba, Japan) and were undertaken in compliance with the institutional 
guidelines regarding animal care and handling. 
 
3.10.1 Xenograft mouse model 
Two types of xenograft mouse models were established for in vivo 
experiments. Subcutaneous gastric cancer xenograft mouse models were 
established by injecting N87 (8.5 x 106) cells in the gluteal region 
subcutaneously to 5 w old BALB/cSIc-nu/nu female mice (Japan SLC, 
Shizuoka, Japan) 2 w before the experiment. The PMGC mouse models 
were established by i.p. injecting luciferase-transfected N87/Luc cells (3 x 
105) into 5-week-old B17/Icr-scid/scidJcl (homo) female mice (CLEA 
Japan, Tokyo, Japan) 1 week before the experiment.    
 
 
3.10.2 Biodistribution 
The biodistribution of 211At-trastuzumab was determined using both s.c. 
and PMGC xenograft mouse models. 211At-trastuzumab was injected into 
the tail vein (s.c. xenograft model) or the peritoneal cavity (both xenograft 
models). Between four and six mice were killed at 1, 3, 6, 12, and 24 h 
post-injection. Tumor, whole blood, and major tissues were then sampled. 
All samples were weighed and the activity of 211At was measured using a c 
counter (Aloka, Tokyo, Japan). The %ID/g was then calculated. The 211At 
activity levels were measured in both the feces and urine of the PMGC 
model mice up to 24 h after the i.p. injection of 211At-trastuzumab and 
the %ID was thereby calculated. 
 
3.10.3 Radioimmunotherapy in s.c. mice 
RIT was performed to the mice 2 w after cell implantation. Mice were 
divided into 4 groups and their average tumor volume was 80.7 ± 7.7 mm3. 
Mice received single injection of PBS, trastuzumab, 0.1 or 0.5 MBq of 
211At-trastuzumab from the tail vein. All protein doses were adjusted to the 
same amount by adding the intact antibody. The tumor size and body 
weight were measured twice a week and the number of white blood cell 
was counted at fixed intervals. The tumor volume was calculated as length 
x width x height x 0.5. When the tumor volume reached 1,200 mm3, the 
mice were euthanized. The relative tumor volume was calculated by 
dividing the tumor volume on the day by the volume at day 0.  
 
3.10.4 Radioimmunotherapy in PMGC mice.  
These PMGC model mice then underwent RIT at 1 week after cell 
inoculation. Mice received a single i.p. injection of PBS, trastuzumab, 
non-carrier 211At (1 MBq), or 211At-trastuzumab (0.1 or 1 MBq). All protein 
doses were adjusted to the same amount (3.78 µg) by the addition of intact 
antibody except for non-carrier 211At. Tumor growth in the PMGC mice 
was monitored every week using an in vivo bioluminescence imaging 
Fusion system (Vilber Lourmat, Marne-la-Val_ee, France). 
Bioluminescence from PMGC was captured for 10 s at 10 min after the 
injection of luciferin (10 mg/mL in PBS, 300 µL/mouse). The total 
bioluminescence intensity in the abdominal region was quantified using 
Bio-1D software (Vilber Lourmat). The relative tumor intensity was 
calculated by dividing the tumor luminescence intensity on the day by the 
level at day 0. Bodyweights and white blood cell counts were determined at 
fixed intervals. 
Blood biochemistry on glutamic oxaloacetic transaminase, glutamic 
pyruvate transaminase, blood urea nitrogen, and creatinine of mice injected 
with 211At-trastuzumab (1 MBq) was carried out using DRI-CHEM 
(Fujifilm, Tokyo, Japan) on the day before injection and at 1, 7, and 14 
days post-injection. The mice were euthanized when the tumor luciferase 
intensity in the abdominal region reached 1.5 x 107 photons. 
 
3.11 Immunofluorescence and Immunohistochemical staining 
Cells were fixed with 4% paraformaldehyde and permeabilised with 1% 
Triton X-100 (Sigma-Aldeich, Japan) twice for 10 min each time. Both 
primary and secondary antibodies mouse anti-γH2AX antibody (MERCK 
MILLIPORE) and anti-mouse IgG-FITC (MERCK MILLIPORE) were 
diluted with 4% BSA/PBS. Cells were incubated with primary antibody for 
1 h at 37˚C followed washing with PBS and 1 h incubation with secondary 
antibody. Vectashild containing DAPI (Vector lab, CA, USA) was added to 
stain the DNA and covered with cover glass.  
PMGC samples were either fixed with 10% buffered formalin and 
embedded in paraffin or filled with OTC compound after dissected from 
mouse and sectioned at 4 µm and 8 µm thickness, respectably. HER2 
expression in PMGC was conformed by HER2 immunohistchemical 
staining using Histofine® HER2 kit (Nichirei Biosciences, Tokyo, Japan) 
following the manufacture’s instructions. Immunofluorescence staining of 
γH2AX in frozen section of PMGC was performed by fixing frozen section 
with 70% ethanol, blocking, incubated with primary antibody (mouse 
anti-γH2AX) for 2 h and secondary antibody (anti-mouse IgG-FITC) for 
another h, finally slide was mounted with Vectachield mounting medium. 
Microscopic images were captured with Axio ImagerA2 microscope with 
microscope camera AxioCam 506 Color (Zeiss, Germany) using 100x and 
40x objective for cell sample and PMGC sample, respectively. 
 
3.12 Statistical analyses.  
Statistical analyses were carried out with JMP version 9 software (SAS 
Institute Japan, Tokyo, Japan) and Statcel 3 software (OMS, Tokorozawa, 
Japan). Tumor volume data were analyzed using two-way repeated 
measures ANOVA. The survival data were analyzed with the Kaplan– 
Meier method. Other data were analyzed by ANOVA followed by the 
Tukey–Kramer post hoc test. A P-value of <0.05 was considered 
significant.  
 
 
 
 
 
 
 
 
Results 
4.1 211At-labeled trastuzumab specifically targets and ablates 
HER2-positive human cancer cells.  
The labeling yield of 211At-trastuzumab was 40.2 ± 6.9% and its 
radiochemical purity was consistently greater than 95% (Fig. 4.1). More 
than 88% of the 211At-trastuzumab yield was stable at 24 h after incubation 
with mouse serum (Fig. 4.2). We determined HER2 expression in three 
human GC cell lines (MKN45, N87, and MKN7), in conjunction with two 
human HER2-overexpressing breast cancer cell lines (SKBR3 and 
AU565).(8,15) The N87, SKBR3, and AU565 cells showed considerably 
higher HER2 expression levels relative to MKN45 cells, in which HER2 
expression was very low. Expression of HER2 was found to be 
approximately 25-, 27-, and 24-fold higher in N87, SKBR3, and AU565 
cells, respectively, than in MKN45 cells (Fig. 4.3). In addition, MKN7 
cells expressed an approximately 6-fold higher HER2 level than MKN45 
cells. Accordingly, we considered N87 cells to be HER2-positive GC cells 
and MKN45 cells to be HER2-negative GC cells. We next determined the 
cell binding of 211At-trastuzumab to N87 and MKN45 cells. The cell 
binding ratios of 211At-trastuzumab to N87 cells were much higher than 
those to MKN45 cells (Fig. 4.4). Moreover, the addition of a 100-fold 
excess of unlabeled trastuzumab markedly decreased the cell binding ratio 
of 211At-trastuzumab to N87 cells, suggesting that this binding was specific 
(Fig. 4.4). 
We next evaluated the in vitro cytotoxicity of 211At-trastuzumab in MKN45, 
N87, SKBR3, MKN7, and AU565 cells by measuring cell viability after 24 
h of exposure (Fig. 4.5). Survival was unaffected in all cases by treatment 
with PBS, trastuzumab, and free 211At. In contrast, a 0.37- or 1.85-kBq dose 
of 211At-trastuzumab effectively killed the N87, SKBR3, and AU565 cell 
populations and reduced the viability of MKN7 cells (Fig. 4.5). MKN45 
cells were unaffected by 0.37 kBq 211At-trastuzumab and only marginally 
affected by 1.85 kBq 211At-trastuzumab (Fig. 4.5). Quantitative cell 
viability data revealed that 211At-trastuzumab significantly reduced with the 
PBS and unlabeled trastuzumab controls (P < 0.05; Fig. 4.6). 
 
  
  
Fig. 4.1 High-performance liquid chromatography chart of 
211At-trastuzumab. 
 
Fig. 4.2 Serum stability of 211At-trastuzumab up to 24 h incubation in 
murine serum, evaluated with RPC by methanol precipitation. Two 
independent experiments were performed in duplicate (n=2). Data 
represent mean ± SD. 
  
Fig. 4.3 HER2 expressions of MKN45, N87, SKBR3, MKN7 and AU565 
cells. α-tubulin as loading control. Ratios of bind intensity of HER2 
relative to α-tubulin are indicated below the images. 
 
 
Fig. 4.4 Cell binding ratio of 211At-trastuzumab to N87 and MKN45 cells 
with/without trastuzumab (mAb) block. Bar legends are indicated in the 
graph. Three independent experiments were performed in triplicate (n=3). 
 
 
Fig. 4.5 A representative image of stained survived cells after 7 d post 24 h 
treatment with PBS control, trastuzumab (Tras), 211At (0.37, 1.85 kBq) or 
211At-trastuzumab (211At-Tras; 0.37, 1.85 kBq). 
Fig. 4.6 Quantification of the cell viability in cells treated with 
211At-trastuzumab for 7 d. Results in Figure 4.5 are quantified. Bar legends 
are indicated in the graph. Three independent experiments were performed 
in triplicate (n=3). All data represent mean ± SD (P<0.05, *vs Control, †vs 
Tras) 
4.2 211At-trastuzumab shows antitumor activity against s.c. xenografts 
of HER2-positive GC cells.  
To investigate the potential antitumor activity of 211At-trastuzumab against 
human GC cells in vivo, we examined the antitumor effects of 
211At-trastuzumab in nude mice bearing s.c. N87 tumors (Fig. 4.8; 4.9). 
Prior to treatment, the tissue uptake of 211At was measured to analyze the 
biodistribution of 211At-trastuzumab (0.5 MBq) in s.c. xenografts. This 
biodistribution analysis revealed that the uptake of i.v. injected 
211At-trastuzumab increased in the s.c. tumor over time, peaking at 
approximately 12.5 ± 4.0%ID/g at 24 h after the injection (Fig. 4.7). The 
spleen showed the highest uptake (23.7 ± 8.6%ID/g) in all tissues at 1 h 
post-injection, which decreased over time to 7.0 ± 1.9%ID/g after 24 h. The 
uptake in the whole blood peaked at 3 h after injection (27.1 ± 4.7%ID/g) 
and decreased thereafter. Uptake of 211At-trastuzumab in the thyroid and 
stomach remained high, even at 24 h post-injection (14.3 ± 8.4%ID/g and 
18.0 ± 8.1%ID/g, respectively). 
To evaluate its therapeutic efficacy in s.c. HER2-positive GC xenografts, a 
single dose of 211At-trastuzumab (0.1 or 0.5 MBq) was i.v. injected into 
mice bearing an s.c. N87 xenograft. An equivalent protein amount of 
unlabeled trastuzumab and PBS were injected as controls. There was no 
significant difference in the relative tumor volume between the control and 
trastuzumab-treated mice (Fig. 4.8). Both groups treated with 0.1 or 0.5 
MBq 211At-trastuzumab showed a significant suppression of tumor growth 
compared with the PBS control group (P < 0.05) and the 0.5 MBq 
211At-trastuzumab dose significantly suppressed tumor growth compared 
with unlabeled trastuzumab (P < 0.05) (Fig. 4.8). Mice treated with 0.1 or 
0.5 MBq 211At-trastuzumab had a significantly prolonged median survival 
(52 and >84 days, respectively) compared with the PBS and unlabeled 
trastuzumab treated controls (38 and 31 days, respectively; Fig. 4.9). No 
significant differences were found in the bodyweights among any of the 
treatment groups (Fig. 4.10). The white blood cell counts sharply decreased 
only in the mice injected with 0.5 MBq 211At-trastuzumab and recovered 
after 3 weeks (Fig. 4.11). 
  
  
Fig. 4.7 Biodistribution of 211At-trastuzumab in mice with subcutaneous 
xenograft of N87. Uptakes (%ID/g) of 211At in tumor and other organs at 1, 
3, 6, 12, 24-h after intravenous injection of 211At-trastuzumab (0.5 MBq). 4 
mice were used for all each time point. All data represent mean ±SD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 Relative tumor volume in each mouse enrolled in this study. 
Tumor volume before the treatment was considered as 100%. 6 mice were 
enrolled to all of the treatment groups but trastuzumab (7 mice). All plots 
were interrupted when one mouse enrolled reached endpoint. All data 
represent mean ±SD (P<0.05, *vs Control, †vs Tras).  
Fig. 4.9 Kaplan-Meier survival curves of s.c. mice  (P<0.05, *vs Control, 
†vs Tras). 
Fig. 4.10 Body weight of mice after treatment. All plots were interrupted 
when one mouse enrolled reached endpoint. All data represent mean ±SD.  
 
 
Fig. 4.11 The number of white blood cell of mice after treatment. All plots 
were interrupted when one mouse enrolled reached endpoint. All data 
represent mean ±SD.  
4.3 Establishment of a xenograft mouse model of PMGC.  
We established a xenograft mouse model of PMGC that allowed tumor 
growth to be monitored by in vivo bioluminescence imaging (Figs. 4.13). 
N87/Luc cells, which are N87 cells that stably express luciferase, were 
generated by lentiviral infection (Fig. 4.12). The bioluminescence activity 
of the N87/Luc cells correlated well with the cell number (Fig. 4.12a,b). 
The level of HER2 expression in the N87/Luc cells was nearly equivalent 
to that in N87 cells (Fig. 4.12c). A mouse model of PMGC was generated 
by i.p. injection of N87/Luc into SCID mice (Fig. 4.13). Peritoneal 
metastasis of GC could be seen around the liver, pancreas, and peritoneal 
region by in vivo bioluminescence imaging (Fig. 4.13a–c). Human 
epidermal growth factor receptor 2 was found to be strongly expressed in 
xenograft tumors in PMGC mice (Fig. 4.13d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.12 Establishment of N87/Luc cells. 
(a) Representative immunofliorescemce images of concentrations of 
N87/Luc cells (0.7-11 x 104 cells) after 10 min incubation of 
luciferin(10mg/ml, 50 µl/well) . (b) Quantified data of (a). Experiment was 
performed in quadruple. Data represent mean ±SD. (c) HER2 expressions 
of N87 and N87/Luc cells. α-tubulin as loading control. Ratios of bind 
intensity of HER2 relative to α-tubulin are indicated below the images. The 
band of N87 is same with Fig. 4.3. 
 
 
Fig. 4.13 Establishment of PMGC xenofraft mouse models. 
(a) Representative chemiluminescence images of PM in the PMGC 
xenofraft mouse models captured 10 min after injection of luciferin with 
abdomen closed. A color scale is indicated luminescence intensity per pixel 
(Min=1,000, Maxi=65,000).  Representative, same mouse with (a), (b) 
chemiluminescence and (c) visual images of PM in the PMGC xenofraft 
mouse models captured 20 min after injection of luciferin with abdomen 
opened. A color scale is indicated luminescence intensity per pixel 
(Min=1,500, Maxi=13,000). Circles highlight visible tumor lesion (c). (d) 
HER2 immunohistochemical staining of PMGC dissected from xenograft 
mouse model. Scale bar = 20µm. 
 
 
 
 
  
4.4 More efficient delivery of 211At-trastuzumab to PMGC with i.p. 
rather than i.v. injection.  
To optimize the system of delivery of 211At-trastuzumab to PMGC in our 
mouse model, we measured the tumor uptake of 211At in HER2-positive 
PMGC mice in order to compare the biodistribution of 211At-trastuzumab 
between i.p. and i.v. injected animals (Fig. 4.14). 211At-trastuzumab (1 
MBq) was injected into the mice either by i.p. or i.v. routes, and the major 
tissues, including the PMGCs, were sampled at different time points. The 
maximum tumor uptake of 211At in the i.p. group was 63.9 ± 52.6%ID/g at 
3 h, whereas it was 18.1 ± 8.6%ID/g at 12 h in the i.v. group. The overall 
uptakes in the whole blood and spleen were also lower in the i.p. group 
than in the i.v. group. These data suggest that i.p. injection more efficiently 
delivers 211At-trastuzumab to HER2-positive PMGCs without an 
undesirable distribution to other tissues. 
  
Fig. 4.14 Biodistribution of 211At-trastuzumab in mice with peritoneal 
metastasis of N87. Uptakes (%ID/g) of 211At in tumor and other organs at 1, 
3, 6, 12, 24-h after intraperitoneal (upper) or intravenous (bottom) injection 
of 211At-trastuzumab (1 MBq). Five mice (for intraperitoneal injection) or 4 
mice (for intravenous injection) were used for all each time point. All data 
represent mean ±SD. 
 
 
 
 
  
4.5 Locoregionally administered 211At-trastuzumab efficiently treats 
HER2-positive PMGC in a mouse model.  
We evaluated the therapeutic efficacy of 211At-trastuzumab against 
HER2-positive PMGC in our mouse model (Figs. 4.15; Fig. 4.16; Table 1). 
The PMGC mice received a single i.p. injection of PBS, unlabeled 
trastuzumab, free 211At (1 MBq), or 211At-trastuzumab (0.1 or 1 MBq) 8 
days after N87/Luc implantation. The tumor growth was monitored 
longitudinally in each group by in vivo bioluminescence imaging (Fig. 
4.15a). Representative bioluminescence images of the mice from each 
group are shown in Figure 4.15(b). Tumor growth was evident in the 
PMGC mice injected with PBS, unlabeled trastuzumab, free 211At, and 0.1 
MBq 211At-trastuzumab. In contrast, a single injection of 1 MBq 
211At-trastuzumab reduced the tumor burden at 3 weeks after injection, with 
the tumors becoming undetectable at 5–7 weeks after treatment. The 
relative bioluminescence signal changes in the tumors in all of the treated 
PMGC mice are shown in Figure 16(a). Trastuzumab and PBS injections 
had little to no effect on tumor growth in the PMGC model. Tumor growth 
appeared to be stable until 20 days after treatment with free 211At and 
resumed thereafter. In PMGC mice treated with 0.1 MBq 211At-trastuzumab, 
some mice appeared to have stable disease but ultimately showed disease 
recurrence. However, in five of the six mice treated with 1 MBq 
211At-trastuzumab, the tumors shrank or stopped growing from 4 days after 
treatment and had disappeared or were still growth arrested at 60 days after 
treatment. Only a single mouse that received a 1-MBq dose of 
211At-trastuzumab showed tumor growth, which was possibly due to 
misinjection. The therapeutic results of 211At-trastuzumab in the PMGC 
model are presented in Table 1. All mice treated with PBS control, 
unlabeled trastuzumab, and 211At (1 MBq) showed tumor progression and 
reached the endpoint (a tumor luciferase intensity of 1.5 x 107) within 60 
days of treatment. Two of the six mice that received 0.1 MBq 
211At-trastuzumab showed a 50% reduction in the tumor but eventually also 
reached the endpoint. Two of the six mice that received a 1-MBq dose of 
211At-trastuzumab had undetectable tumors; a further three of these mice 
showed a 50% or 90% tumor reduction, and one mouse still showed tumor 
growth. The five mice showing tumor regression had not reached the 
endpoint by 60 days after treatment. Not surprisingly, survival was 
significantly prolonged in the 1 MBq 211At-trastuzumab group compared 
with all of the other groups (P < 0.05). The median survival outcomes were 
26, 29, 50, and 43 days in the PBS control, unlabeled trastuzumab, 1 MBq 
211At, and 0.1 MBq 211At-trastuzumab groups, respectively (Fig. 17). 
  
Fig. 4.15 (a) Experiment time curse of radioimmunotherapy to PMGC 
mouse model. (b)Representative chemiluminescence images of tumor 
growth in the peritoneal metastasis mouse models treated with PBS 
(Control), trastuzumab (Tras), 211At (1 MBq), or 211At-trastuzumab 
(211At-Tras; 0.1 or 1 MBq). Shown are images the day before the treatment 
and 3, 5, 7 w after treatment. A color scale is indicated luminescence 
intensity per pixel (Min=1,000, Maxi=65,000). 
 
Table 1 Tumor response up to 60 d after treatment  in the peritoneal 
metastasis mouse models treated with PBS (Control), trastuzumab (Tras), 
211At (1 MBq), or 211At-trastuzumab (211At-Tras; 0.1 or 1 MBq). * : The 
number of mice, which the PMGC was undetectable once. †, ‡: The 
number of mice, which the total luminescence intensity of PMGC was 
reduced to 50 and 90%, respectively. §: The number of mice, which the 
total luminescence intensity of PMGC did not reach the endpoint (1.5 x 
107). 
  
Fig. 4.16 Quantified relative tumor luminescence intensity in each mouse 
enrolled in this study. Luminescence intensity before the treatment was 
considered as 100%. 6 mice were enrolled to all of the treatment groups but 
control (5 mice). 
 
Fig. 4.17 Kaplan-Meier survival curves of mice (P<0.05,  *vs Control, †vs 
Tras, ‡vs 211At).  
4.6 Excretion and adverse effects of i.p. injected 211At-trastuzumab in 
PMGC mouse model.  
To evaluate the possible adverse effects of 211At-trastuzumab in our PMGC 
model, we monitored whether any changes occurred in the bodyweight or 
number of leukocytes in the treated mice. No apparent bodyweight loss was 
evident in any of the treated groups during the observation period (Fig. 
4.18). In addition, no leukocytopenia was found in any of the groups, 
including the 1 MBq 211At-trastuzumab mice (Fig. 4.19). To then assess the 
excretion of 211At from the body, we measured its levels in feces and urine. 
The total 211At activity in the urine (7.3%ID) of the PMGC mice up to 24 h 
post i.p. injection of 211At-trastuzumab was much higher than that in the 
feces (1.3%ID) (Fig. 4.20). Biochemical examination of glutamic 
oxaloacetic transaminase, glutamic pyruvate transaminase, and blood urea 
nitrogen at 1, 7, and 14 days post-injection revealed no significant change 
compared to the pre-treatment level (Fig. 4.21). Creatinine was not 
detected in any of the mice preinjection or at 1, 7, or 14 days post-injection.  
 
  
Fig. 4.18 Body weight of mice after treatment. Plots were interrupted when 
one mouse enrolled reached endpoint. Data represent mean ±SD. 
 
 
Fig. 4.19 The number of white blood cell of mice after treatment. Plots 
were interrupted when one mouse enrolled reached endpoint. Data 
represent mean ±SD. 
Fig. 4.20 The activities of 211At in both feces and urine of PMGC model 
mice up to 24 h after i.p. injection of 211At-tras (1 MBq). Six mice were 
used for the experiment (n=6) and data represent mean. Bar legends are 
indicated in the graph. 
 
 
Fig. 4.21 The data of biochemical examination of GOT (red), GPT (blue) 
and BUN (green) up to 14 d after injection of  i.p. 211At-tras (1 MBq). 
Five mice were used for 0 and 1 d, and four mice were used for 7 and 14 d. 
The data of each mouse are shown in the graph. 
 
 
 
4.7 DNA damage is induced in tumor cells by 211At-trastuzumab.  
To better understand how 211At-trastuzumab kills tumor cells, we examined 
the DNA damage in these cells both in vitro and in vivo by detecting 
γH2AX foci using immunostaining and Western blot analysis. Clusters of 
γH2AX foci were clearly observed in N87 cells treated with 
211At-trastuzumab for 24 h, but barely detectable in N87 cells treated with 
PBS or unlabeled trastuzumab (Fig. 4.22). In addition, MKN45 cells 
treated with even the maximum dose of 211At-trastuzumab (37 kBq) 
showed barely any γH2AX foci (Fig. 4.22). The level of γH2AX, evaluated 
by Western blotting, also showed a clear dose-dependency and increased in 
N87 cells treated with 211At-trastuzumab compared to PBS and unlabeled 
trastuzumab (Fig. 4.22). A slightly increased level of γH2AX was observed 
in MKN45 cells with a high-dose treatment of 211At-trastuzumab (18.5 and 
37 kBq), but was still much lower than that in N87 cells (Fig. 4.22). Dense 
clusters of γH2AX foci could clearly be observed in N87 cells treated with 
18.5 kBq 211At-trastuzumab after 24 h in an immunofluorescence image 
taken at a higher magnification (Fig. 4.22). Clusters of γH2AX foci were 
clearly evident in tumors dissected from the PMGC model mice at 6 h after 
the i.p. injection of 1 MBq 211At-trastuzumab, compared to the control and 
unlabeled trastuzumab-treated animals (Fig. 4.23). As shown in Figure 4.23, 
clusters of γH2AX foci were located in the same area showing HER2 
expression (Fig. 4.23). These observations indicate that 211At-trastuzumab 
specifically induces DNA DSBs in HER2-positive PMGC cells. 
  
Fig. 4.22 Representative immunofliorescemce images of γH2AX foci in 
GC cells after treated with 211At-trastuzuma. (a) γH2AX foci in MKN45 
and N87 cells treated with either PBS, Tras or 211At-trastuzumab (1.85, 3.7, 
18.5, 37 kBq). Scale bar = 20µm. (b) γH2AX expressions in N87 and 
MKN45 cells treated with either PBS, Tras or 211At-trastuzumab (1.85, 3.7, 
18.5, 37 kBq). α-tubulin as loading control. Ratios of bind intensity of 
γH2AX relative to α-tubulin are indicated below the images. (c) γH2AX 
foci in N87 cells treated with either PBS or 18.5 kBq of 211At-trastuzumab. 
Scale bar = 10µm. 
 
Fig. 4.23 Representative immunofliorescemce images of γH2AX foci in 
PMGC after treated with 211At-trastuzumab. (a) γH2AX foci in PMGC after 
6 hour injected PBS, Tras or 1 MBq of 211At-trastuzumab. Scale bar = 
20µm. (b) HER2 and γH2AX foci in PMGC after 3 hour injected treated 1 
MBq of 211At-trastuzumab. Scale bar = 20µm. 
 
 
 
  
Discussion 
Despite recent advances in chemotherapy and molecular targeted therapies 
directed against advanced GC, the prognosis of patients with PMGC is still 
miserably poor. In our current study, we show that 211At-trastuzumab 
specifically targets HER2-positive GC cells, both in vivo and in vitro, and 
successfully inhibits tumor growth and improves survival in PMGC model 
mice. Our in vitro cytotoxicity analyses showed that 211At-trastuzumab 
specifically kills HER2-positive cells, but not MKN45 cells that have little 
expression of HER2. Free 211At had little effect in either cell type in vitro. 
Given that radiolabeled trastuzumab is internalized into the cells it 
binds,(8) our present data suggest that targeted cell binding and 
internalization of 211At-trastuzumab is required for 211At to exert its 
cytotoxic effects. A specific targeting strategy is critically important to 
maximize the cell-killing effects of α-particle emitters in α-RIT. 
We clearly found from our current experiments that i.p. administration is 
superior to i.v. injection in delivering 211At-trastuzumab to tumors 
disseminated in the peritoneal cavity. Considering that 211At decays with a 
half-life of 7.2 h, a faster accumulation of high-dose 211At to the target 
lesion is required to maximize its antitumor effects. Intraperitoneal delivery 
also resulted in a lower distribution of 211At to other normal tissues, 
including the whole blood and spleen, compared with i.v. injection. These 
data strongly suggest that locoregional therapy helps to avoid adverse 
effects. Moreover, in this regard, we found that an i.v. injection of 
211At-trastuzumab (0.5 MBq) resulted in acute but recoverable 
leukocytopenia in s.c. xenografts. 
In contrast, no leukocytopenia or bodyweight loss was evident in i.p. 
injected mice, even those injected with a 1-MBq dose of 211At-trastuzumab. 
In addition, no significant biochemical changes in either the liver or kidney 
were observed in mice treated with 1 MBq 211At-trastuzumab. We conclude, 
therefore, that i.p. delivery of 211At-trastuzumab is far more suitable in 
terms of undesirable adverse effects. Recent studies have explored the 
utility of i.p. α-RIT in various preclinical cancer models.(16–18) 
Furthermore, a previous clinical trial reported that the therapeutic absorbed 
dose of i.p. a-RIT in ovarian cancer at the peritoneal cavity was >100 times 
greater than that in the red bone marrow without significant toxicity.(19) 
Thus, i.p. a-RIT appears to be a clinically feasible approach. 
We further showed from our current analysis that a-RIT with 
211At-trastuzumab suppressed tumor growth in both s.c. GC xenografts and 
PMGC xenografts. In our PMGC mice, five of the six that received only a 
single locoregional treatment with 211At-trastuzumab showed improved 
survival and a drastic reduction in tumor burden. We also found that 
211At-trastuzumab induced massive DNA DSBs in HER2-positive GC cells, 
but not in HER2-negative cells. Unlabeled trastuzumab of an equal protein 
level to that of the labeled antibody could not induce DSB in N87 cells. We 
thus speculate that α-particles emitted from 211At-trastuzumab efficiently 
induced irreparable DSBs in N87 cells and thereby caused tumor 
shrinkage. 
A previous study showed that 211At-trastuzumab is effective against 
radioresistant ovarian i.p. tumors in mice.(20) In that report, a single i.p. 
injection of 0.8 MBq 211At-trastuzumab did not achieve a tumor-free 
outcome in the mice. However, 0.4 MBq radiolabeled antibody combined 
with unlabeled trastuzumab resulted in a complete eradication of the 
tumors. Additionally, 500 µg unlabeled trastuzumab, which is a more than 
100-fold higher amount of protein than that used in our present 
experiments, had a better therapeutic result compared to 0.8 MBq 
211At-trastuzumab monotherapy. In the present study, we did not fully 
investigate the effects of unlabeled trastuzumab on human GC N87 cells. 
Further studies are therefore needed to clarify the effects of unlabeled 
antibody on a-RIT. 
The success of trastuzumab has led us to develop a novel type of 
HER2-targeted drug. Previously, trastuzumab emtansine, an antibody–drug 
conjugate carrying the cytotoxic agent emtansine bound to trastuzumab, 
has shown antitumor activity against HER2-positive tumors and emerged 
as a powerful therapeutic option for advanced or metastatic breast cancer 
that is resistant to trastuzumab.(21,22) We speculate, however, that because 
a single α-particle atom can kill a target cell,(11,12) the cytotoxic effects of 
211At-trastuzumab could even be superior to those of trastuzumab-based 
antibody–drug conjugates. 
In principle, locoregional α-RIT reduces the risk of the hematological 
toxicities that are the most worrying adverse effects of this treatment 
approach.  
 
  
Conclusion 
We propose that locoregional α-radioimmunotherapy using 
211At-trastuzumab is a safe and highly effective therapy and is a very 
promising future therapeutic option for PMGC. 
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Abbreviations 
211At        astatine-211 
209Bi        bismuth-209 
DNA        deoxyribonucleic acid 
DSB        double-strand break (in the DNA macromolecule) 
GC         gastric cancer 
HER2       human epidermal growth factor receptor-2 
i.p          intraperitoneal(ly) 
i.v.          intravenous(ly) 
LET         linear energy transfer 
NCS         N-Chlorosuccinimide 
m-MeATE    N-Succinimidyl-3-(trimethylstannyl)benzoate 
PBS         phosphate buffered saline 
%ID/g        percent injected dose per gram of tissue 
PMGC       peritoneal metastasis of gastric cancer 
RIT          radioimmunotherapy 
SPECT       single photon emission computed tomography 
s.c.           subcutaneous(ly)  
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